Revolution Medicines, Inc. Payments to Acquire Marketable Securities
Revolution Medicines, Inc. (RVMD) reported Payments to Acquire Marketable Securities of $2.25 billion for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- Revolution Medicines, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $2.04B, a 285.11% increase year-over-year.
- Revolution Medicines, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $209.73M, a 58.88% decline year-over-year.
- Revolution Medicines, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $296.49M, a 57.35% decline year-over-year.
- Revolution Medicines, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $459.04M, a 25.81% increase year-over-year.
- Revolution Medicines, Inc. payments to acquire marketable securities for fiscal 2025 was $1.79B, a 16.00% decline from fiscal 2024.
- Revolution Medicines, Inc. payments to acquire marketable securities for fiscal 2024 was $2.14B, a 101.77% increase from fiscal 2023.
- Revolution Medicines, Inc. payments to acquire marketable securities for fiscal 2023 was $1.06B, a 72.81% increase from fiscal 2022.
- Revolution Medicines, Inc. payments to acquire marketable securities for fiscal 2022 was $612.77M, a 8.72% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.04B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.25B 10-Q · filed 2026-08-05 | $2.54B derived: sum of 3 quarters · filed 2026-08-05 | $3.00B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $209.73M 10-Q · filed 2026-05-06 | $506.22M derived: sum of 2 quarters · filed 2026-05-06 | $965.26M derived: sum of 3 quarters · filed 2026-05-06 | $1.49B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $296.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $755.52M derived: sum of 2 quarters · filed 2026-02-25 | $1.28B derived: sum of 3 quarters · filed 2026-08-05 | $1.79B 10-K · filed 2026-02-25 |
| 2025-09-30 | $459.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $988.33M derived: sum of 2 quarters · filed 2026-08-05 | $1.50B 10-Q · filed 2025-11-05 | $2.19B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $529.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.04B 10-Q · filed 2026-08-05 | $1.73B derived: sum of 3 quarters · filed 2026-08-05 | $2.10B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $510.04M 10-Q · filed 2026-05-06 | $1.21B derived: sum of 2 quarters · filed 2026-05-06 | $1.57B derived: sum of 3 quarters · filed 2026-05-06 | $1.94B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $695.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.06B derived: sum of 2 quarters · filed 2026-02-25 | $1.43B derived: sum of 3 quarters · filed 2026-02-25 | $2.14B 10-K · filed 2026-02-25 |
| 2024-09-30 | $364.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $739.73M derived: sum of 2 quarters · filed 2025-11-05 | $1.44B 10-Q · filed 2025-11-05 | $1.96B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $374.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $1.08B 10-Q · filed 2025-08-06 | $1.60B derived: sum of 3 quarters · filed 2026-02-25 | $1.77B derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $701.68M 10-Q · filed 2025-05-07 | $1.22B derived: sum of 2 quarters · filed 2026-02-25 | $1.39B derived: sum of 3 quarters · filed 2026-02-25 | $1.57B derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $519.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $689.64M derived: sum of 2 quarters · filed 2026-02-25 | $865.82M derived: sum of 3 quarters · filed 2026-02-25 | $1.06B 10-K · filed 2026-02-25 |
| 2023-09-30 | $170.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $346.21M derived: sum of 2 quarters · filed 2024-11-06 | $539.31M 10-Q · filed 2024-11-06 | $699.65M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $176.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $369.27M 10-Q · filed 2024-08-07 | $529.61M derived: sum of 3 quarters · filed 2025-02-26 | $742.57M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $193.10M 10-Q · filed 2024-05-08 | $353.43M derived: sum of 2 quarters · filed 2025-02-26 | $566.40M derived: sum of 3 quarters · filed 2025-02-26 | $694.05M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $160.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $373.30M derived: sum of 2 quarters · filed 2025-02-26 | $500.95M derived: sum of 3 quarters · filed 2025-02-26 | $612.77M 10-K · filed 2025-02-26 |
| 2022-09-30 | $212.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $340.62M derived: sum of 2 quarters · filed 2023-11-06 | $452.43M 10-Q · filed 2023-11-06 | $563.25M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $127.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $239.47M 10-Q · filed 2023-08-08 | $350.28M derived: sum of 3 quarters · filed 2024-02-26 | $518.53M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $111.82M 10-Q · filed 2023-05-08 | $222.63M derived: sum of 2 quarters · filed 2024-02-26 | $390.88M derived: sum of 3 quarters · filed 2024-02-26 | $669.12M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $110.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $279.06M derived: sum of 2 quarters · filed 2024-02-26 | $557.30M derived: sum of 3 quarters · filed 2024-02-26 | $671.34M 10-K · filed 2024-02-26 |
| 2021-09-30 | $168.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $446.48M derived: sum of 2 quarters · filed 2022-11-07 | $560.52M 10-Q · filed 2022-11-07 | $605.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $278.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $392.27M 10-Q · filed 2022-08-09 | $437.15M derived: sum of 3 quarters · filed 2023-02-27 | $631.20M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $114.04M 10-Q · filed 2022-05-09 | $158.91M derived: sum of 2 quarters · filed 2023-02-27 | $352.97M derived: sum of 3 quarters · filed 2023-02-27 | $558.13M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $44.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $238.93M derived: sum of 2 quarters · filed 2023-02-27 | $444.10M derived: sum of 3 quarters · filed 2023-02-27 | $544.13M 10-K · filed 2023-02-27 |
| 2020-09-30 | $194.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $399.22M derived: sum of 2 quarters · filed 2021-11-10 | $499.26M 10-Q · filed 2021-11-10 | $527.84M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $205.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $305.20M 10-Q · filed 2021-08-11 | $333.79M derived: sum of 3 quarters · filed 2022-02-28 | $422.06M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $100.04M 10-Q · filed 2021-05-10 | $128.62M derived: sum of 2 quarters · filed 2022-02-28 | $216.90M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $28.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $116.86M derived: sum of 2 quarters · filed 2022-02-28 | $172.27M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $88.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $143.68M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $55.41M 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |